What are the current hypertension treatment guidelines for Black adults?

Hypertension Management in Black Adults

For Black adults with hypertension, initial pharmacologic therapy should consist of a thiazide-type diuretic or calcium channel blocker (CCB), either as monotherapy for low-risk patients or as combination therapy for most others, with a target blood pressure of <130/80 mmHg.

Initial Drug Selection

The most recent guidelines consistently recommend avoiding ACE inhibitors or ARBs as initial monotherapy in Black patients 1, 2, 3. This recommendation stems from historical evidence showing blunted blood pressure responses to renin-angiotensin system (RAS) blockers when used alone in this population.

First-Line Options:

Step 1 (Initial Therapy):

• Low-dose ARB + DHP-CCB combination, OR
• DHP-CCB + thiazide/thiazide-like diuretic combination 2

The 2020 International Society of Hypertension guidelines specifically recommend starting with combination therapy in Black patients rather than monotherapy, recognizing that most will require multiple agents 2.

Step 2 (If BP remains uncontrolled):

• Increase to full doses of initial combination 2

Step 3 (Add third agent):

• Add the missing component: either diuretic or ACE inhibitor/ARB 2

Step 4 (Resistant hypertension):

• Add spironolactone, or if not tolerated: amiloride, doxazosin, eplerenone, clonidine, or beta-blocker 2

Blood Pressure Targets

Target BP: <130/80 mmHg for most Black adults 2, 3. This is more aggressive than older targets and reflects evidence that Black patients benefit from intensive BP control given their disproportionate burden of:

• Stroke (36% reduction with treatment in SHEP trial) 4
• Heart failure
• Chronic kidney disease
• Premature cardiovascular death

The 2022 ACC/AHA harmonization document emphasizes that combination therapy is specifically recommended for Black patients to achieve these targets 1, 5.

Critical Nuances and Pitfalls

The ACE Inhibitor/ARB Controversy

While guidelines recommend against ACE inhibitors/ARBs as initial monotherapy, they are not contraindicated and should be added as part of combination therapy 2. Recent evidence challenges the race-based exclusion of RAS blockers:

• When used in combination therapy, ACE inhibitors and ARBs show comparable efficacy across all populations 6, 7, 8
• Evidence-based combination regimens (CCB or thiazide + RAS blocker) show no racial disparity in BP response 8
• One comprehensive program achieved >80% control rates in both Black and White patients using a race-agnostic algorithm 8

Clinical Pearl: Don't avoid RAS blockers entirely—they become essential components of multi-drug regimens and are particularly important if the patient develops proteinuria, heart failure, or post-MI indications 3, 6.

Combination Therapy is the Rule, Not the Exception

The ACC/AHA specifically recommends combination therapy for Black patients because:

• Most require ≥2 drugs to achieve target BP 1, 5
• Single-pill combinations improve adherence 1
• Black patients often present with BP ≥20/10 mmHg above target, mandating combination therapy 1, 5

Avoid These Common Errors:

1. Don't use the relaxed 150/90 mmHg target from JNC-8 for patients ≥60 years—this was controversial and may disproportionately harm Black patients who have higher cardiovascular risk 4

2. Don't delay treatment waiting for lifestyle modifications alone in high-risk patients (those with CVD, CKD, diabetes, or organ damage)—start medications immediately 2

3. Don't use beta-blockers as first-line therapy unless there's a specific cardiac indication (post-MI, heart failure, atrial fibrillation) 1

4. Don't combine ACE inhibitors with ARBs—this is potentially harmful 1, 5

Monitoring and Follow-Up

• Achieve target BP within 3 months 2
• Use home BP monitoring (target <135/85 mmHg) or 24-hour ambulatory monitoring (target <130/80 mmHg) to confirm office readings 2
• Measure BP in both arms at first visit; use the arm with higher readings 2

Special Considerations

For Black patients with:

• CKD with proteinuria: RAS blockers become preferred agents regardless of race 3, 6
• Heart failure: Follow standard HF guidelines (ACE inhibitor/ARB/ARNI + beta-blocker + MRA + SGLT2 inhibitor) 3
• Diabetes: Same initial therapy approach (CCB or thiazide preferred), but lower threshold for adding RAS blocker 1, 3

The Bigger Picture

Black adults face a 5.4-year shorter life expectancy than White adults, with hypertension being the single largest contributor to this disparity 4. They experience:

• 57.1% hypertension prevalence vs. 43.6% in non-Hispanic Whites 6
• Earlier onset and more severe disease
• Higher rates of resistant, nocturnal, and masked hypertension 9

Therefore, aggressive treatment with combination therapy targeting <130/80 mmHg is justified and evidence-based, despite some guidelines suggesting more relaxed targets for older adults 4.